Search Results for: First Clinical Milestone Achieved in
Articles
First Clinical Milestone Achieved in Collaboration Between AbCheck & Lilly February 7, 2017
AbCheck s.r.o., a technology company focusing on the discovery and optimization of high-quality human antibodies, recently announced the achievement of...Kynos Therapeutics Announces Positive Top-Line Results From First-in-Human Phase I Study of its KMO Inhibitor April 23, 2024
Kynos Therapeutics Ltd recently announced the key findings from the first-in-human Phase 1 trial of its lead drug candidate, KNS366....SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases November 15, 2023
SciRhom GmbH recently announced the achievement of a significant milestone in its development pipeline. The company has submitted a Clinical...Ocean Biomedical Announces Positive Preclinical Oncology Data for VRON-0300 November 14, 2023
Ocean Biomedical, Inc. recently announced its joint venture partner, Virion Therapeutics, LLC, recently presented highly compelling preclinical oncology data at...MoonLake Immunotherapeutics Achieves Landmark Milestone With Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa June 26, 2023
MoonLake Immunotherapeutics recently announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe….
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement With GSK June 21, 2023
SCYNEXIS, Inc. recently announced the achievement of a $25-million performance-based development milestone under its exclusive license agreement with GSK for….
NovelMed Phase 1 Clinical Trial Shows Inhibition of the Alternative Pathway & Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody for PNH Patients June 5, 2023
NovelMed Therapeutics, Inc. recently announced topline results from First-in-Human Phase 1 clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086…..
Valo Therapeutics Announces First Patient Dosed With PeptiCRAd-1 - Innovative Immuno-Oncology May 23, 2023
Valo Therapeutics Oy (ValoTx) recently announced the first patient has been treated in its Phase 1 trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor….
Omnix Medical Announces Excellent Topline Data From Phase 1 Clinical Trial of Novel Anti-Infective May 8, 2023
Omnix Medical recently announced positive top-line results from the Phase 1 clinical trial of its lead compound OMN6, an anti-infective...Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain & Function in Rheumatoid Arthritis February 28, 2023
Incannex Healthcare Limited recently announced it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug….
uniQure Announces FDA Approval of First Gene Therapy for Adults With Hemophilia B November 23, 2022
Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels….
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis June 28, 2022
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical...Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills June 28, 2022
With the realization of the first successful customer fills, Vetter has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria. Further batches are already planned,….
First Patient Dosed in Second Phase 2 Add-on Ketamine Trial in Treatment-Resistant Depression June 8, 2022
HMNC Brain Health, together with Develco Pharma, recently announced the dosing of the first patient in their second Phase 2...FDA Approves Dermavant’s VTAMA (Tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Years May 24, 2022
Dermavant Sciences recently announced the US FDA has approved VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes….
Spero Therapeutics Announces Positive Topline Results From Phase 1 Bronchoalveolar Lavage Clinical Trial February 16, 2022
Spero Therapeutics, Inc. recently announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously...Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+/HER2- Breast Cancer November 30, 2021
Olema Pharmaceuticals, Inc. recently announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2...Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline With a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) & Other Rare Ocular Surface Diseases November 15, 2021
Kala Pharmaceuticals, Inc. recently announced it has acquired Combangio, Inc., a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases…..
PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial November 5, 2021
PDC*line Pharma recently announced the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 Phase 1/2 clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer….
Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership October 5, 2021
Avacta Group plc recently announced a preclinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an….
